| To
assist in the fund-raising process, the company commissioned
an independent review of:
-
the revenue-generating potential of
its services, technology, and internal R&D projects
-
the viability of its proposed strategy
and plans going forward.
The objectives for the client
-
Assessment of the company's service
offerings, technology platforms, R&D projects and
collaborative programmes in terms of:
-
achievements to date and future development
plans
-
robustness of IP
-
key competitors and competitive position
-
revenue projections and timelines
-
key risks and merits.
-
To address questions raised by the investors
in terms of:
-
market overview (e.g. size and segmentation;
market trends; entry barriers)
-
prospects for the company (e.g. value
of current alliances; potential upside from the current
portfolio; key risks; critical success factors; steps
and timing for adding value; exit opportunities).
The programme of work
-
A review and analysis of documentation
provided by the company.
-
Meetings and in-depth interviews with
key company staff.
-
An iterative process of desk research.
-
A programme of external interviews with
pharmaceutical industry and healthcare professionals to
identify key market needs, to obtain views on the strengths
and weaknesses of existing and developing competitive
technologies, and to gauge the level of interest in the
company's services and technologies.
-
A review of the IP situation.
-
Valuation of the company at its planned
exit date (bottom-up and via benchmarking).
|
|
The
deliverables to the client |
|
|
| |
The
project achievements |
-
The project resulted in the client
raising its required level of capital from the investors.
-
The client gained confidence from
an independent assessment of its plans, and clarification
of the critical success factors and key risks going
forward.
Added value
Bridgehead Consulting presented its
independent findings directly to the investors. This
assisted the company in raising the capital needed to
allow it to take its key technology platforms through
to proof-of-principle (in order to attract high quality
licensing deals) and also to take its first development
products into clinical trials. |
| |
|
PDF Version